Www.ebmt.org #EBMT2015 IEWP – EBMT 2015 Business Meeting Monday 08.00 23 rd March 2015.

Slides:



Advertisements
Similar presentations
Cord Blood Transplantation: Umbilical Blood As Hematopoietic Stem Cell Source Analysis of theoretical/clinical advantages/disadvantages Comparison with.
Advertisements

Minimal Residual Disease in Hematologic Neoplasms Lloyd M. Stoolman, M.D. Professor of Pathology and Director, Clinical and Research Flow Cytometry Laboratories.
Primary Immunodeficiencies in Africa: a preliminary idea Bousfiha AA, Esser M, Ailal F, Jeddane L, Boukari R, El Marsafi A, Eley B, Barbouche R, Bejaoui.
Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.
PRIMARY & SECONDARY ANTIBODY DEFICIENCY.
Hematopoietic stem cell transplantation
Blood Product Reimbursement Report 4 th QuarterNovember 2009Volume 1, Number This information is provided as a service to assist hospitals and other.
The role of transplant for CML in the imatinib era Dr Wendy Ingram Consultant Haematologist University Hospital of Wales.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.
Allogeneic Stem Cell Transplantation: The Journey
Faecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) in immunocompromised (IC) pts: Efficacy and safety International, multi-centre,
Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.
DR. YETUNDE T. ISRAEL-AINA PAEDIATRICIAN, UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY BENIN BLOOD AND MARROW TRANSPLANT WORKSHOP, UNIVERSITY OF BENIN.
Gene Therapy Trials for PID:A Nursing Perspective Jin Hua Xu-Bayford Clinical Nurse Specialist Gene Therapy The child first and.
Severe Combined Immunodeficiency Syndrome A heterogeneous group of congenital disorders which results in the absence of antigen-specific T and B cell responses.
5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].
Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
1 Assessing Cancer Risk & Assuring Safe Use of Topical Immunosuppressants: Recent History Susan K. Cummins, MD, MPH Medical Team Leader OCTAP and OPT.
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SEVERE COMBINED IMMUNODEFICIENCY (SCID) I.Tezcan, T.Turul, D. Uckan, M.Cetin, O.Sanal,
EU COST Action IS 1402 Berlin, WG1 group/subgroup meetings.
Adenosine-Deaminase (ADA) Deficiency ADA is responsible gene in ~20% SCID. Often fatal, if untreated, due to infections. It was the first form of SCID.
(A) the hematopoietic stem cell transplanted (HSCT) recipients only (B) both autologous and allogeneic transplanted recipients (C) both solid organ and.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
Introduction to the NHLBI Context. Agenda  Introduction to the NMDP / CIBMTR  Forms being curated  Progress update  Description of review process.
Margaret L. Green, Wendy M. Leisenring, Hu Xie, Roland B. Walter, Marco Mielcarek, Brenda M. Sandmaier, Stanley R. Riddell and Michael Boeckh Blood NUM.
G. Lucchini on behalf of the EBMT PDWP SCT in pediatric AML in 1CR: does the conditioning regimen matter? Scientific Day 12 th May, 2016 London.
Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies  Marcelo.
Successful Treatment of Richter Transformation with Ibrutinib in a Patient with Chronic Lymphocytic Leukemia following Allogeneic Hematopoietic Stem Cell.
Case Western Reserve University and University Hospitals of Cleveland
EBMT Activity Survey Teams Patients Transplants
Hepatic Veno-occlusive disease/Sinusoidal obstruction syndrome
Figure 1. Study participant flowchart
Hepatic Veno-occlusive disease/Sinusoidal obstruction syndrome
Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 
Advances in HSCT: Highlights From the 2013 BMT Tandem Meetings
Miguel-Angel Perales MD
Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients  Josephus P.J. van Gestel,
LWP and lymphoma-related meetings and presentations
Peripheral T-Cell Lymphoma in 2013
EBMT Activity Survey Teams 39,313 Patients 43,636 Transplants
Beata Wolska – Kuśnierz Department of Immunology
Immunodeficiencies.
EBMT Activity Survey Teams Patients Transplants
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.
Outcomes of Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency: A Report from the Australian and New Zealand Children’s Haematology Oncology.
Whom should you refer for allogeneic stem cell transplantation?
Expert Perspectives on HSCT: Planning for Success
Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?  Arjan C. Lankester, Franco Locatelli, Peter Bader, Eva Rettinger,
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
Safety, Pharmacokinetics, and Efficacy of Palifermin in Children and Adolescents with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic.
Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients  Josephus P.J. van Gestel,
Timing for HCT Consultation
Hematopoietic Stem Cell Transplantation for Patients with AML
Donald B. Kohn, MD, Caroline Y. Kuo, MD 
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
JAK2 INHIBITORS AND ALLOGRAFTING
Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies  Rebecca A. Marsh, MD, Kyle M. Hebert,
Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting.
Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp 
Allogeneic Stem Cell Transplantation for Aplastic Anemia
Fig. 1 HSCT: A platform for cellular therapies.
Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies  Marcelo.
Hematopoietic Stem Cell Transplantation Dr . Ghassemi A Associate professor of pediatric Hematologist Oncologist & stem cell transplantation.
Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study  Francesca Ferrua, MD, Stefania.
Bridge to transplant following Bv+Bs regimen.
CD45RA depletion in HLA-mismatched allogeneic hematopoietic stem cell transplantation for primary combined immunodeficiency: A preliminary study  Fabien.
Primary cellular immunodeficiencies
Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies by Christian Chabannon, Jurgen Kuball, Attilio Bondanza, Francesco.
Hematopoietic stem cell transplantation in HCV-infected patients
Fig. 2 From HSCT to cellular therapy.
Presentation transcript:

#EBMT2015 IEWP – EBMT 2015 Business Meeting Monday rd March 2015

2 Agenda IEWP sessions at EBMT 2015 Leuven Workshop – “How to transplant a patient with PID” April 24 th IEWP Autumn meeting – Seville October 16 th -18 th Metabolic diseases – update Gene Therapy – update Recent publications Update on current studies New study proposals News from EBMT/ESID AOB

3 Paediatrics WP – C ̧ amlica Hall Marina Cavazzano – Gene therapy clinical trials: Recent progress Inborn Errors WP C ̧ amlica Hall Beatriz Morillo-Gutierrez – Treosulfan-based conditioning for CGD Giovanna Lucchini – SCT in AML: Does the conditioning regimen matter? Christina Peters – Myeoablative chemoconditioning for allogeneic SCT in children with ALL Arjan Lankester – HSCT for SCID below age two: an update by the European Registry (SCETIDE) Jaap Jan Boelens – Outcome of Duke-Eurocord study on outcomes of CBT for leukodystrophy Bénédicte Neven - HSCT For Patients With PID In Europe: An Update By The European Registry (SCETIDE) IEWP Sessions – Istanbul 2015 Tuesday 24th March 2015

4

5

6 Metabolic Diseases sub-committee - Update

7 Gene Therapy Sub-committee - Update

8 Gungor T, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383: IF Bontant T, et al. Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT. Bone Marrow Transplant. 2014;49:276-9 IF Publications

9 Angelucci E, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99: IF Fuchs S, et al. Patients with T ⁺ /low NK ⁺ IL-2 receptor γ chain deficiency have differentially-impaired cytokine signaling resulting in severe combined immunodeficiency. Eur J Immunol. 2014;44: IF Publications

10 Wehr C, et al. Multicenter experience in hematopoietic stem cell transplantation in 25 patients with common variable immunodeficiency. J Allergy Clin Immunol 2015 (in press) IF Aydin SE, et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options. J Clin Immunol 2015;35: IF Publications

11 DNA repair defects - outcome of HSCT: an EBMT IEWP/ CIBMTR study – manuscript draft almost ready to be circulated HSCT for CD40 ligand deficiency: results from an EBMT IEWP study – study closed, presented at ESID, to be presented at EBMT, manuscript in preparation** The PCID Study: Update And Baseline Features Of The First Fifty Patients - ESID presentation, manuscript in process Nijmegen Breakage Syndrome: clinical and immunological features, long-term outcome and treatment options. Submitted to J Clin Immunol – revision in progress Cord Blood Tx in Leukodystrophies (IEWP/Eurocord) – – Oral presentation at EBMT Rituximab post HSCT Defibrotide treatment for TMA (IEWP/PDWP) – data analysis commencing Reticular Dysgenesis: International Survey on Clinical Presentation, Transplantation and Outcome – Manuscript prepared Update on current studies

12 –Retrospective outcome of CGD (Tx or no) correlated with residual NADPH function (joint IEWP/PIDTC) - commencing –Analyse the next data set from SCETIDE (SCID/PID) – Oral presentations at EBMT, Manuscript commencing –Outcome of HSCT with Treosulfan conditioning for CGD - Oral presentations at EBMT, Manuscript commencing –Longterm (>20yr) outcome of HSCT for SCID (IEWP/PIDTC) – ESID fellow commencing April 2015 –HSCT for VPS45 deficiency - commencing –IPEX – Outcome +/- HSCT (with PIDTC) – commencing Update on current studies

13 New Study Proposals –HSCT for DOCK8 - commencing

14 New Study Proposals

15 Leiden Statistical unit – Arjan Lankester update Ethical approval Ideas for a prospective study……… –CGD Treo or Bu (need Treop PK first) New Studies